JP Morgan Week 2025 – Albert Seymour
The annual JP Morgan Healthcare Conference in San Francisco attracts companies at all stages, from brand-new start-ups to established clinical biotechs. And, as might be expected, some of the most exciting, novel science is happening in early-stage companies.
This year at the show, pharmaphorum editor-in-chief Jonah Comstock met with Albert Seymour, CEO of Seamless Therapeutics, a genetics medicines company leveraging new technology that allows them to edit the genes in a wide range of cells with the enzyme recombinase.
Seymour explains how the company’s unique platform is opening up the possibility of in vivo gene therapy, as well as the steps they’re taking to position themselves to develop this novel idea into a viable platform technology.
He also talks about the investment environment for early stage biotechs like his and why the company decided to set up shop in Boston.
Check out the full video to learn more about this up-and-coming genetic medicines company.
